U.S. DOD to Start New Trial with Pluristem's PLX-R18 Cell Therapy Against ARS

The U.S. Department of Defense’s (DOD) Armed Forces Radiobiology Research Institute (AFRRI) is to undertake a pilot study in non-human primates (NHP) evaluating Pluristem Therapeutics’ PLX-R18 as a treatment for acute radiation syndrome (ARS) prior to and within the first 24 hours of radiation exposure. The AFRRI is part of the Uniformed Services University of Health Sciences (USU).Pluristem’s PLX-R18 is an off-the-shelf placental expanded (PLX) cell therapy product generated f